The stock is in a recovery uptrend from a deep drawdown, with a 1-year price change of -14.8% but a strong 6-month gain of +14.8%. Currently trading at $112.41, it sits at 81.8% of its 52-week range ($92.42 low to $137.46 high), indicating a rebound from the lows but still below the highs. This positioning suggests the stock is gaining momentum but has not yet reclaimed its prior peak, offering potential upside if the trend continues. Short-term momentum is accelerating sharply, with a 1-month change of +10.7% and a 3-month change of +15.6%, outpacing the S&P 500's 1-month gain of 4.1%. This divergence from the negative 1-year trend signals a potential trend reversal, supported by a relative strength 1-month of 6.6% versus the market. The stock's beta of 0.28 indicates it is significantly less volatile than the market, making it a defensive holding. Key support is at the 52-week low of $92.42, while resistance is at the 52-week high of $137.46. A breakout above $137.46 would signal a resumption of the long-term uptrend, while a breakdown below $92.42 could indicate renewed weakness. The low beta suggests the stock is less sensitive to broad market swings, which may appeal to risk-averse investors.

Revenue has been declining, with the most recent quarterly revenue of $4.08 billion in Q4 2025 representing a -17.2% year-over-year decline. Over the past four quarters, revenue has trended downward from $4.84 billion (Q1 2025) to $4.08 billion, indicating a deceleration. The consumer tissue segment contributed $1.519 billion in the latest quarter, but overall growth is pressured by category headwinds and portfolio changes. This declining revenue trajectory raises concerns about the company's ability to grow organically, though the Kenvue acquisition may provide a future catalyst. Profitability remains solid, with net income of $499 million in Q4 2025 and a gross margin of 35.9%, which has been relatively stable around 35-36% over recent quarters. The net margin of 12.2% is healthy, though slightly compressed from 12.3% in the prior quarter. Operating margin of 12.4% is consistent with industry norms for consumer staples. The company is profitable and generates consistent earnings, with EPS of $1.50 in Q4 2025. The balance sheet shows a debt-to-equity ratio of 4.86, which is elevated, indicating significant leverage. However, free cash flow (TTM) of $2.38 billion provides ample coverage for dividends and debt service. The current ratio of 0.75 suggests tight liquidity, but strong operating cash flow of $972 million in Q4 2025 supports financial flexibility. ROE of 134.6% is extremely high, driven by leverage, while ROA of 10.2% reflects efficient asset use. The company's ability to generate cash is a key strength, with FCF yield of approximately 7.1% based on market cap.